Thailand Lung Cancer Therapeutics Market Report 2022 to 2030

Thailand Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Thailand Lung Cancer Therapeutics Market will reach a value of $68 Mn from $36 Mn in 2022, growing at a CAGR of 8.5% during 2022-2030. The Lung Cancer Therapeutics Market in Thailand is dominated by a few domestic pharmaceutical companies such as Siam Bioscience, Bangkok Labs, and Bio Net-Asia. The Lung Cancer Therapeutics Market in Thailand is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Thailand lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10THPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Dr. Vishwa Modhia

Buy Now

Thailand Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Thailand Lung Cancer Therapeutics market will reach a value of $68 Mn from $36 Mn in 2022, growing at a CAGR of 8.5% during 2022-2030.

Thailand is an upper middle-income developing country located in Southeastern Asia bordering the Andaman Sea and the Gulf of Thailand. Thailand is the 12th most populous country in Asia, with a population of 67.9 Mn people. According to the most recent Global Cancer Incidence, Mortality, and Prevalence Report published in 2018, lung cancer is the most frequent type of cancer in Thailand, accounting for 14.1% of all malignancies (of which, 70 % were diagnosed in the advanced disease stage). Furthermore, lung cancer has the second-highest fatality rate (18.7%) in Thailand, trailing only liver cancer, which has the highest mortality rate (20.3%) as of 2018. The 2013 Thailand National Cancer Control Program identified cigarette use, asbestos exposure, and air pollution as risk factors for lung cancer.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Thailand reached 22,296 or 5.01% of total deaths. The age-adjusted Death Rate is 21.30 per 100,000 population ranks Thailand 47^th in the world. Thailand's government spends 4.4% of its GDP on healthcare.

Thailand Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

There are currently 35 radiation therapy facilities operating throughout Thailand: 16 in Bangkok, 13 in the north, two in the centre, two in the south, one in the east, and one in the west. Because it achieves maximum tumour control with minimal treatment effects, 3D-CRT is currently the minimum technological standard and the most often used RT method for the treatment of lung cancer in Thailand. In Thailand, the surgical procedure for stages I and II are usually invariably video-assisted thoracoscopic. Thailand serves as a regional hub because of its long coasts and proximity to rapidly growing Asian markets. These aspects could boost Thailand's Lung Cancer Therapeutics market.

Market Restraints

Because of the high cost and lack of funding, robotic-assisted thoracic surgery is rarely used. Surgeons have also had limited experience with this method. Only three institutes in Bangkok have robotic-assisted surgical equipment, which is largely utilised for urologic procedures. Thailand has fewer than 200 active thoracic surgeons who are members of the Thai Society of Thoracic Surgeons. Although thoracic surgeons can be found throughout the country, the majority of them work in Bangkok. The length of time patients must wait for lung cancer surgery is a major problem.

Another significant issue in Thailand is the availability of drugs. Although all cancer medications approved by the US Food and Drug Administration (FDA) for NSCLC therapy are also approved and available in Thailand, the approval process by Thailand FDA typically takes 2 to 3 years after the US FDA clearance. These factors may deter new entrants into the Thailand Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Siam Bioscience: Siam Bioscience is a Thai pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Bangkok Lab & Cosmetic: Bangkok Lab & Cosmetic is a Thai pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Bio Net-Asia: Bio Net-Asia is a Thai pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Mega Lifesciences Public Company Limited: Mega Lifesciences is a Thai pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer

Healthcare Policies and Reimbursement Scenarios

The Food and Drug Administration (FDA) and the National Health Security Office manage the regulation and reimbursement of lung cancer therapies in Thailand (NHSO). To be reimbursed, lung cancer therapies must be included on the National List of Essential Medicines and the National List of Essential Medical Supplies (NLEMS). The National Health Security Office's (NHSO) gold card universal healthcare plan benefitted at least 250,000 cancer patients in 2022, up from an annual average of 100,000 recipients in the previous five years. The gold card's cancer coverage, which includes surgery, chemotherapy, and radiotherapy, stems from the NHSO board's "Cancer Anywhere" policy, which strives to provide fast care across the country.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.